Evaluation of Survivin and E2F3 mRNAs in Blood of Prostate Cancer Patients

Abstract

Until now, there is no efficient non-invasive biomarker for the early diagnosis of prostate cancer. PSA is the main non-invasive diagnostic test available, however, it lacks specificity thusnovel biomarkers are needed. E2F3 and survivin have major roles in prostate cancer development and progression. Therefore, this study was conducted to examine and assess the gene expression level of E2F3 and survivinin the peripheral blood of prostate cancer patients. Therefore, this study was conducted to examine and assess the gene expression level of E2F3 and survivin in the peripheral blood of prostate cancer patients. This was a prospective observational study in which a total of 125subjectswere enrolled and categorized into three groups as follows I. Normal control group:It included twenty-five normal healthy males. II. Benign prostatic hyperplasia (BPH) group: It included twenty-five patients suffered from BPH. III. Prostate cancer group: It included seventy-five patients with pathologically and radiologically proven prostate adenocarcinomaand did not receive any medical or surgical therapeutic intervention.